Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMIR P MACWAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neuromuscular Medicine

NPI
1265558753
CMS profile
741673
Location
RANCHO MIRAGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$128,305.32

250 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $65,677.86 127
US WorldMeds, LLC $49,893.58 87
Allergan Inc. $9,548.28 27
Grifols USA, LLC $3,136.82 6
Grifols Shared Services North America, Inc. $35.67 1
CSL Behring $12.28 1
Retrophin, Inc. $0.83 1

Page 3 of 5; records 101–150 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMIR P MACWAN

NPI 1265558753 · CMS profile ID 741673

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neuromuscular Medicine

RANCHO MIRAGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265558753?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMIR P MACWAN, NPI 1265558753, CMS profile ID 741673. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265558753?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SAMIR P MACWAN, NPI 1265558753, CMS profile ID 741673. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265558753?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SAMIR P MACWAN, NPI 1265558753, CMS profile ID 741673, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 250 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1265558753?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

250 matching records · $128,305.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 250 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 250.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $50.0009/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564823 CMS
US WorldMeds, LLC $41.6909/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466045 CMS
US WorldMeds, LLC $3,500.0009/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466031 CMS
US WorldMeds, LLC $21.8609/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466041 CMS
US WorldMeds, LLC $224.0009/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466245 CMS
US WorldMeds, LLC $68.9809/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466249 CMS
US WorldMeds, LLC $501.4309/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466035 CMS
Alexion Pharmaceuticals, Inc. $2,600.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564955 CMS
Alexion Pharmaceuticals, Inc. $2,100.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564967 CMS
Alexion Pharmaceuticals, Inc. $87.5708/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564915 CMS
Alexion Pharmaceuticals, Inc. $87.5808/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564831 CMS
Alexion Pharmaceuticals, Inc. $14.4008/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564863 CMS
Alexion Pharmaceuticals, Inc. $87.5808/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564997 CMS
Alexion Pharmaceuticals, Inc. $2,350.0008/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564959 CMS
US WorldMeds, LLC $17.7808/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466027 CMS
Alexion Pharmaceuticals, Inc. $31.7308/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564833 CMS
US WorldMeds, LLC $150.8008/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466059 CMS
US WorldMeds, LLC $3,000.0008/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466065 CMS
Allergan Inc. $61.0008/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670753637 CMS
CSL Behring $12.2808/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683882793 CMS
Alexion Pharmaceuticals, Inc. $24.1308/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564637 CMS
Alexion Pharmaceuticals, Inc. $79.9308/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564787 CMS
Alexion Pharmaceuticals, Inc. $579.8008/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564789 CMS
Alexion Pharmaceuticals, Inc. $20.2608/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564639 CMS
Alexion Pharmaceuticals, Inc. $79.9208/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564805 CMS
Alexion Pharmaceuticals, Inc. $579.7908/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564809 CMS
Allergan Inc. $400.0007/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670753635 CMS
Allergan Inc. $4.3907/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670753631 CMS
Alexion Pharmaceuticals, Inc. $3.2007/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564633 CMS
Grifols USA, LLC $1,420.0007/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692574021 CMS
Grifols USA, LLC $25.7607/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692576641 CMS
US WorldMeds, LLC $18.1106/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466007 CMS
Alexion Pharmaceuticals, Inc. $2,100.0006/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564935 CMS
Allergan Inc. $125.0006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670753625 CMS
Allergan Inc. $2,000.0006/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670753628 CMS
US WorldMeds, LLC $1,125.4606/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465979 CMS
US WorldMeds, LLC $3,000.0006/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465991 CMS
US WorldMeds, LLC $849.4006/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465975 CMS
US WorldMeds, LLC $2,500.0006/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465985 CMS
US WorldMeds, LLC $138.2506/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699466017 CMS
Alexion Pharmaceuticals, Inc. $89.6806/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564615 CMS
Alexion Pharmaceuticals, Inc. $13.0606/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695564783 CMS
Retrophin, Inc. $0.8305/30/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701822325 CMS
US WorldMeds, LLC $62.9105/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465959 CMS
US WorldMeds, LLC $2,500.0005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465965 CMS
US WorldMeds, LLC $1,250.0005/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465971 CMS
US WorldMeds, LLC $18.0005/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465949 CMS
US WorldMeds, LLC $2,500.0005/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465953 CMS
US WorldMeds, LLC $22.7405/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465911 CMS
US WorldMeds, LLC $149.0005/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699465915 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $128,305.32 250
PY2020 $55,143.66 115
PY2021 $69,391.75 118
PY2022 $127,886.60 181
PY2023 $143,012.68 273
PY2024 $255,899.69 415
PY2025 $203,627.49 315

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,007.57 7
PY2025 Principal investigator $102,789.50 27
PY2024 Principal investigator $131,486.52 36
PY2023 Principal investigator $107,303.81 15
PY2022 Principal investigator $11,541.50 2
PY2021 Principal investigator $8,956.00 4
PY2020 Principal investigator $5,450.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,257.20 12/15/2025 Non-covered Recipient Entity
Southland Neuromuscular
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228730783
Recipient Takeda Pharmaceuticals U.S.A., Inc. $350.00 12/10/2025 Covered Recipient Physician A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223263172
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/10/2025 Covered Recipient Physician A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223263174
Principal investigator 1 ARGENX US, INC. $38,345.86 12/03/2025 Non-covered Recipient Entity
SAMIR MACWAN MD INC
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237156940
Principal investigator 1 ARGENX US, INC. $225.00 12/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141381
Recipient Takeda Pharmaceuticals U.S.A., Inc. $451.00 11/12/2025 Covered Recipient Physician A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223263166
Recipient Takeda Pharmaceuticals U.S.A., Inc. $643.00 11/12/2025 Covered Recipient Physician A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223263168
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,001.00 11/12/2025 Covered Recipient Physician A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223263170
Principal investigator 1 ARGENX US, INC. $70.00 10/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141385
Principal investigator 1 ARGENX US, INC. $70.00 09/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141399
Principal investigator 1 ARGENX US, INC. $195.81 08/22/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141333
Recipient ARGENX US, INC. $4,303.27 08/21/2025 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237140654
Principal investigator 1 ARGENX US, INC. $1,550.00 08/14/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141345
Principal investigator 1 ARGENX US, INC. $1,650.00 08/07/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141348
Principal investigator 1 ARGENX US, INC. $70.00 08/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141393
Principal investigator 1 ARGENX US, INC. $70.00 07/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141388
Principal investigator 1 ARGENX US, INC. $400.00 06/05/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141337
Principal investigator 1 ARGENX US, INC. $70.00 06/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141378
Principal investigator 1 ARGENX US, INC. $18,000.00 05/28/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141341
Principal investigator 1 ARGENX US, INC. $70.00 05/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141373
Principal investigator 1 ARGENX US, INC. $2,000.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141311
Principal investigator 1 ARGENX US, INC. $12,700.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141315
Principal investigator 1 ARGENX US, INC. $2,000.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141318
Principal investigator 1 ARGENX US, INC. $300.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141321
Principal investigator 1 ARGENX US, INC. $2,900.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141325
Principal investigator 1 ARGENX US, INC. $8,200.00 04/11/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141329
Recipient ARGENX US, INC. $2,259.30 04/08/2025 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237140650
Principal investigator 1 ARGENX US, INC. $70.00 04/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141369
Principal investigator 1 ARGENX US, INC. $70.00 03/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141356
Principal investigator 1 ARGENX US, INC. $70.00 02/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141353
Principal investigator 1 Alexion Pharmaceuticals, Inc. $7,938.00 01/30/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185542898
Principal investigator 1 ARGENX US, INC. $3,323.63 01/29/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237141351
Principal investigator 1 ARGENX US, INC. $104.00 01/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141360
Principal investigator 1 ARGENX US, INC. $70.00 01/01/2025 Covered Recipient Teaching Hospital
Eisenhower Medical Center
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy No dispute reported 06/30/2026 1237141365